Century Therapeutics, Inc.

NasdaqCM:IPSC Stock Report

Market Cap: US$382.4m

Century Therapeutics Past Earnings Performance

Past criteria checks 0/6

Century Therapeutics has been growing earnings at an average annual rate of 8.3%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 74.4% per year.

Key information

8.32%

Earnings growth rate

45.61%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate74.44%
Return on equity-40.71%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • Dec 17

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. ( NASDAQ:IPSC ) shareholders have had their patience rewarded with a 32% share price jump in...
Analysis Article • Nov 30

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 08

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Century Therapeutics, Inc.'s ( NASDAQ:IPSC ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...
Seeking Alpha • Jun 20

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Read the full article on Seeking Alpha
Analysis Article • Mar 06

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 01

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response. However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment. Read the full article on Seeking Alpha
Analysis Article • Oct 23

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 25

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Century Therapeutics (NASDAQ:IPSC) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA. CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies. In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. CNTY-101 is derived from a clonal  induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product. Seeking Alpha's Quant Rating views Century (IPSC) as a hold with strong grades for profitability and momentum.

Revenue & Expenses Breakdown

How Century Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:IPSC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-108280
31 Dec 25109-10290
30 Sep 25113-26310
30 Jun 25114-23330
31 Mar 25115-22340
31 Dec 247-127350
30 Sep 243-130350
30 Jun 242-131350
31 Mar 241-133350
31 Dec 232-137350
30 Sep 232-129340
30 Jun 235-127330
31 Mar 236-125330
31 Dec 225-131320
30 Sep 225-127300
30 Jun 222-123280
31 Mar 221-115240
31 Dec 210-96190
30 Sep 210-831612
30 Jun 210-701223
31 Mar 210-621032
31 Dec 200-54940

Quality Earnings: IPSC is currently unprofitable.

Growing Profit Margin: IPSC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IPSC is unprofitable, but has reduced losses over the past 5 years at a rate of 8.3% per year.

Accelerating Growth: Unable to compare IPSC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: IPSC has a negative Return on Equity (-40.71%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 05:38
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Century Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Chen YangBofA Global Research
William MaughanCanaccord Genuity